Efficacy of atorvastatin (10 and 80 mg/day) in patients with stable coronary disease

Trial Profile

Efficacy of atorvastatin (10 and 80 mg/day) in patients with stable coronary disease

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Apr 2018

At a glance

  • Drugs Atorvastatin (Primary)
  • Indications Coronary artery disease
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms TNT
  • Sponsors Pfizer
  • Most Recent Events

    • 05 Apr 2018 Results (n=4853) of analysis estimating individual benefit from PCSK9 inhibition in terms of months gained free of stroke or MI in statin treated patients with stable CAD published in the Heart
    • 04 Apr 2018 Results of post-hoc analysis assessing the relationship between TRL-C and cardiovascular risk, and whether this risk was modifiable among patients receiving statins in the TNT trial published in the Circulation
    • 06 Apr 2017 Results of post-hoc analysis assessing body-weight fluctuations (n=9509) published in the New England Journal of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top